Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Research analysts at Piper Jaffray Companies upped their FY2018 earnings per share (EPS) estimates for Neurocrine Biosciences in a research note issued to investors on Monday, November 5th. Piper Jaffray Companies analyst D. Amsellem now expects that the company will earn $0.14 per share for the year, up from their prior forecast of $0.12. Piper Jaffray Companies currently has a “Buy” rating and a $111.00 target price on the stock. Piper Jaffray Companies also issued estimates for Neurocrine Biosciences’ Q2 2019 earnings at $0.44 EPS, Q3 2019 earnings at $0.52 EPS, Q4 2019 earnings at $0.64 EPS, FY2019 earnings at $1.85 EPS, FY2020 earnings at $4.47 EPS, FY2021 earnings at $5.73 EPS and FY2022 earnings at $8.15 EPS.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Monday, November 5th. The company reported $0.52 EPS for the quarter, topping the Zacks’ consensus estimate of $0.48 by $0.04. The business had revenue of $151.80 million for the quarter, compared to analysts’ expectations of $151.51 million. Neurocrine Biosciences had a negative return on equity of 14.22% and a negative net margin of 16.07%. The business’s quarterly revenue was up 149.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.13) EPS.
Shares of Neurocrine Biosciences stock opened at $106.56 on Wednesday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 9.19 and a current ratio of 9.19. The company has a market capitalization of $10.48 billion, a price-to-earnings ratio of -65.78, a P/E/G ratio of 37.22 and a beta of 0.94. Neurocrine Biosciences has a one year low of $67.32 and a one year high of $126.98.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in NBIX. Victory Capital Management Inc. boosted its position in shares of Neurocrine Biosciences by 60.5% during the third quarter. Victory Capital Management Inc. now owns 605,135 shares of the company’s stock valued at $74,402,000 after purchasing an additional 228,163 shares in the last quarter. Braun Stacey Associates Inc. bought a new stake in shares of Neurocrine Biosciences during the second quarter valued at approximately $14,333,000. Mainstay Capital Management LLC ADV boosted its position in shares of Neurocrine Biosciences by 3,156.2% during the second quarter. Mainstay Capital Management LLC ADV now owns 134,970 shares of the company’s stock valued at $1,624,000 after purchasing an additional 130,825 shares in the last quarter. Boston Advisors LLC boosted its position in shares of Neurocrine Biosciences by 571.3% during the second quarter. Boston Advisors LLC now owns 131,481 shares of the company’s stock valued at $12,917,000 after purchasing an additional 111,896 shares in the last quarter. Finally, American Century Companies Inc. boosted its position in shares of Neurocrine Biosciences by 14.0% during the second quarter. American Century Companies Inc. now owns 566,895 shares of the company’s stock valued at $55,692,000 after purchasing an additional 69,701 shares in the last quarter.
In other news, Director Gary A. Lyons sold 15,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, November 2nd. The stock was sold at an average price of $114.41, for a total value of $1,716,150.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Richard F. Pops sold 5,500 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, October 29th. The stock was sold at an average price of $107.13, for a total value of $589,215.00. Following the completion of the sale, the director now owns 37,759 shares in the company, valued at $4,045,121.67. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by company insiders.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.
Featured Story: Stock Symbols Definition, Examples, Lookup
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.